TB500 TFA | CAS#885340-08-9 | Thymosin beta 4 acetated analog

MedKoo Cat#: 465354 | Name: TB500 TFA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TB-500 is a synthetic version of an active region of thymosin β4. TB 500 promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation. A veterinary preparation known as TB-500 and containing a synthetic version of the naturally occurring peptide LKKTETQ has emerged. The peptide segment (17)LKKTETQ(23) is the active site within the protein thymosin β(4) responsible for actin binding, cell migration and wound healing. The key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus. TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation.

Chemical Structure

TB500 TFA

CAS#TB500 TFA

Theoretical Analysis

MedKoo Cat#: 465354

Name: TB500 TFA

CAS#: TB500 TFA

Chemical Formula: C40H68F3N9O17

Exact Mass: 889.4757

Molecular Weight: 1004.03

Elemental Analysis: C, 47.85; H, 6.83; F, 5.68; N, 12.56; O, 27.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

TB500 TFA 885340-08-9 (free base) 75591-33-4

Synonym

TB500 TFA; TB500 trifluoroacetate salt; TB500; TB 500; TB-500; thymosin β4 acetate; AcLKKTETE;

IUPAC/Chemical Name

acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-glutamyl-L-threonyl-L-glutamic acid, tritfluoroacetic acid

InChi Key

FWYSAPIGICJMKO-PFWNPZQHSA-N

InChi Code

InChI=1S/C38H67N9O15.C2HF3O2/c1-19(2)18-27(41-22(5)50)35(58)43-23(10-6-8-16-39)32(55)42-24(11-7-9-17-40)33(56)46-30(20(3)48)36(59)44-25(12-14-28(51)52)34(57)47-31(21(4)49)37(60)45-26(38(61)62)13-15-29(53)54;3-2(4,5)1(6)7/h19-21,23-27,30-31,48-49H,6-18,39-40H2,1-5H3,(H,41,50)(H,42,55)(H,43,58)(H,44,59)(H,45,60)(H,46,56)(H,47,57)(H,51,52)(H,53,54)(H,61,62);(H,6,7)/t20-,21-,23+,24+,25+,26+,27+,30+,31+;/m1./s1

SMILES Code

O=C(O)CC[C@@H](C(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC(C)=O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,004.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Judák P, Van Eenoo P, Deventer K. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Anal Biochem. 2017 Nov 15;537:69-71. doi: 10.1016/j.ab.2017.09.003. Epub 2017 Sep 5. PMID: 28887173. 2: Zvereva I, Semenistaya E, Krotov G, Rodchenkov G. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteomics. 2016 Oct 21;149:85-97. doi: 10.1016/j.jprot.2016.08.016. Epub 2016 Aug 26. PMID: 27569051. 3: Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W, Thevis M. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. 2016 Jan;39(2):333-41. doi: 10.1002/jssc.201501060. Epub 2015 Dec 15. PMID: 26578461. 4: Semenistaya E, Zvereva I, Krotov G, Rodchenkov G. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug Test Anal. 2016 Sep;8(9):940-9. doi: 10.1002/dta.1890. Epub 2015 Oct 16. PMID: 26472487. 5: Esposito S, Deventer K, Geldof L, Van Eenoo P. In vitro models for metabolic studies of small peptide hormones in sport drug testing. J Pept Sci. 2015 Jan;21(1):1-9. doi: 10.1002/psc.2710. Epub 2014 Dec 3. PMID: 25469748. 6: Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Rev Proteomics. 2014 Dec;11(6):663-73. doi: 10.1586/14789450.2014.965159. Epub 2014 Nov 8. PMID: 25382550. 7: Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014 Dec;101:66-83. doi: 10.1016/j.jpba.2014.05.020. Epub 2014 May 23. PMID: 24906629. 8: Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, Wan TS. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2013 Mar;405(8):2595-606. doi: 10.1007/s00216-012-6697-9. Epub 2013 Jan 15. PMID: 23318763. 9: Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23;1265:57-69. doi: 10.1016/j.chroma.2012.09.043. Epub 2012 Sep 23. PMID: 23084823. 10: Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012 Sep;4(9):733-8. doi: 10.1002/dta.1402. Epub 2012 Sep 7. PMID: 22962027.